Hplc Fat Loss Steroids Furazabol THP Raw Powder Miotolan 1239-29-8

Pharmaceutical Grade Fat Loss Steroids Furazabol THP Raw Powder Miotolan For Bodybuilding Cas 1239-29-8

Quick Detail

Description

Raw Furazabol powder (Miotolan) is a derivative of the anabolic. It differs from by having a furazan ring system in place of the pyrazole. It has a c-17alpha methyl group, which allows it to be taken orally
Intermediates & Fine Chemicals; Pharmaceuticals;

Furazabol (brand names Frazalon, Miotolan), also known as androfurazanol, is an analogue of the anabolic steroid stanozolol. It differs from stanozolol by having a furazan ring system in place of the pyrazole. It has a c-17alpha methyl group, which allows it to be taken orally and causes hepatotoxicity in some individuals.

According to William Llewellyn, author of Anabolics 2007, the cholesterol-lowering effects of furazabol are a myth. In the 1970s, research studies showed that furazabol along with many other orally-active AAS like Anavar (oxandrolone) lowered total serum cholesterol.[citation needed] It was subsequently established that the cholesterol reduction from oral AAS was the result of suppressed HDL levels. As such, it would be expected that furazabol, like other oral anabolic steroids, while reducing total cholesterol levels would still adversely affect the HDL/LDL ratio and increase the risk of cardiovascular disease.

The Canadian sprinter Ben Johnson tested positive for stanozolol after winning the gold medal in the 100 meter sprint at the 1988 Summer Olympics.[citation needed] His doctor, Jamie Astaphan, maintains that his urine sample was sabotaged because Johnson was administered furazabol, which was not an IOC banned substance at the time.[citation needed] Subsequently, training partner and fellow Charlie Francis athlete Angela Issajenko (Taylor), in her book "Running Risks" outlined a theory stating Ben Johnson actually was using stanozolol. She substantiated this by stating that her supply of what she thought was furazabol was retested following the Dubin Inquiry and was found to be stanozolol, explaining the positive test.

The effects of Miotolan (furazabol) are similar to Winstrol except instead of having an adverse effect on cholesterol values, therapeutic doses of Furazabol purportedly improve a person’s blood lipid profile. As such, Furazabol was prescribed in Japan under the trade name Miotolan in the 1970s as a treatment for hypercholesterolemia. Both Furazabol and Winstrol are modified Dihydrotestosterone (DHT) molecules; the former possesses a furazan group and the latter a pyrazole group. This presumably accounts for the different effects on blood lipids.

According to William Llewellyn, author of Anabolics 2007, the cholesterol-lowering effects of Furazabol are a myth. In the 1970s, research studies showed that Furazabol along with many other orally-active AAS like Anavar (oxandrolone) lowered total serum cholesterol. It was subsequently established that the cholesterol reduction from oral AAS was the result of suppressed HDL levels. As such, it would be expected that Furazabol, like other oral anabolic steroids, while reducing total cholesterol levels would still adversely affect the HDL/LDL ratio and increase the risk of cardiovascular disease.

Diversion of this obscure pharmaceutical steroid to the black market rarely occurred while it was being manufactured by Daiichi Seiyaku Company in Japan. However, a number of underground labs (UGL) have produced limited quantities of Furazabol in recent years. Additionally, a non-methylated derivative of Furazabol called Furaguno is currently being sold over-the-counter on the sport nutrition market in the United States in 2006 and 2007.